Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Assembly Biosciences (ASMB) Income from Continuing Operations (2016 - 2025)

Assembly Biosciences has reported Income from Continuing Operations over the past 11 years, most recently at 22090000.0 for Q4 2025.

  • Quarterly results put Income from Continuing Operations at 22090000.0 for Q4 2025, up 313.74% from a year ago — trailing twelve months through Dec 2025 was 6122000.0 (up 84.76% YoY), and the annual figure for FY2025 was 6122000.0, up 84.76%.
  • Income from Continuing Operations for Q4 2025 was 22090000.0 at Assembly Biosciences, up from 9196000.0 in the prior quarter.
  • Over the last five years, Income from Continuing Operations for ASMB hit a ceiling of 22090000.0 in Q4 2025 and a floor of 62788000.0 in Q4 2021.
  • Median Income from Continuing Operations over the past 5 years was 15658000.0 (2023), compared with a mean of 16650250.0.
  • Biggest five-year swings in Income from Continuing Operations: crashed 461.45% in 2021 and later skyrocketed 313.74% in 2025.
  • Assembly Biosciences' Income from Continuing Operations stood at 62788000.0 in 2021, then skyrocketed by 64.33% to 22395000.0 in 2022, then surged by 51.05% to 10962000.0 in 2023, then grew by 5.72% to 10335000.0 in 2024, then surged by 313.74% to 22090000.0 in 2025.
  • The last three reported values for Income from Continuing Operations were 22090000.0 (Q4 2025), 9196000.0 (Q3 2025), and 10198000.0 (Q2 2025) per Business Quant data.